fbpx

Retroperitoneal Cancer

Sarcoma of Retroperitoneal Space

Male, 64 years

Patient Internal ID: 952415

ICD-10 code

C48.0 Malignant Neoplasm of Retroperitoneal Space

Diagnosis (Incl. Metastases/Stage) and Year

2010
Retroperitoneal Sarcoma of the Retroperitoneal Space TxN0M0 G1 (2010). Disease recurrence in 2012 and 2020. Disease recurrence and progression in September of 2021 – Abdominal Metastases.

Previous Treatment

Surgery (Resection of lipoma), Radiation Therapy, Surgery (Hemicolectomy and Nephrectomy), Surgery (Hemicolectomy) Immunosuppressant (Sirolimus), Surgery (Hernioplasty and Alloplastic).

Prognosis and Survival Expectation

Liposarcomas are relatively rare tumors. The prognosis for Advanced Liposarcoma remains poor, with a median overall survival of ~15 months

Treatment Provided

Autologous DCV (7 doses) and CIK (14 doses) over a period of 15 months.
Additionally, the patient received Mistletoe Therapy.

Patient Survival/Condition and Year
Date of Review: 01/01/2024

The patient has survived for 14 years since the diagnosis and for 15 months since the metastatic disease progression. No signs of disease progression has been seen for a year. It can be concluded that the addition of Immunotherapy, alongside Surgery and Radiation Therapy, has been beneficial in disease stabilisation.

Disclaimer

We encourage you to learn more about your condition and treatment options to make informed decisions about your healthcare. However, please keep in mind that not all information available online or in other sources is accurate or relevant to your specific situation. It’s important to rely on credible, evidence-based sources such as official medical websites, peer-reviewed publications, or information provided by professional healthcare organizations. Always discuss any information you find with your healthcare provider before making decisions, as they can help clarify details, address concerns, and ensure the information is appropriate for your unique needs.